Praxis Precision Medicines (PRAX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is PRAX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Praxis Precision Medicines, Inc. ( PRAX ) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Joon Lee - UBS Inves…

I maintain a Strong Buy on Praxis Precision Medicines, with a $601 fair value, 85% above the November 12 close. The valuation falls from $664 primarily after correcting the share count for pre-funded warrants and options…

Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027…

Praxis Precision Medicines, Inc. ( PRAX ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 9:30 AM EST Company Participants Marcio Souza - President, CEO & Director Tim Kelly - CFO & Treasurer Conf…

FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD study of relutrigine…

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that o…

BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it wil…

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that o…

Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companie…

Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty ratings firms that are covering the stock, MarketBeat reports. Two analysts have…

Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, under…

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that …

Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned a consensus rating of "Buy" from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports.…

Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $391.64 and last traded at $376.38, with a volume of 58…

Handelsbanken Fonder AB acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The ins…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

